Stories Tagged as
Botox is a multi-billion dollar, potentially deadly monopoly
The product comes from a substance so lethal that it could be used as a potential agent of bioterrorism.
Pharma: an industry shaped by shareholder value
Big drug companies today have remade their business models.
The only way to stop inversions might be tax reform
The Pfizer-Allergan merger is out, but what about inversions across the board?
Pfizer abandons $160B Allergan deal
A change in U.S. tax laws has put a halt to the merger.
Pfizer's tax-driven Allergan merger
Regulators want to cut down on these deals, but this one is full-speed ahead.
Pfizer and Allergan agree to $160 billion "inversion"
The deal would create the largest pharmaceutical company in the world.
Activist investors help shareholders, right?
A new study says activist investors generated 48 percent average gain for companies they targeted.
Botox might help migraines
Botox eases wrinkles, but can it also ease migraine headaches? Allergan says it can. The company that produces Botox reports that two large tests...